A new generation of anticoagulants, namely Xarelto and Pradaxa, have been at the center of much controversy in recent times. The manufacturers of these drugs have seen a significant increase in sales of their drugs, thanks in part to how convenient they are compared to more traditional blood thinners. However, the significant sales of these drugs can also be linked to Gregory Lip, a British heart doctor who has extensive ties to the pharmaceutical industry.
Lip has been a paid speaker and consultant for these manufacturers for many years and has also served on treatment guidelines panels, most of which have recommended that more people use these new drugs. One scale in particular, adopted in the U.S. in 2014, suggested than an additional 1 million people take the drug. However, external experts warn that the scale can lead to people with a lower or intermediate risk being put on these newer anticoagulants and risk internal bleeding.
According to the Milwaukee Journal Sentinel/MedPage Today, Lip has received money from at least 5 companies that market and/or make these new anticoagulants. As a British citizen, Lip does not have to disclose the amount of money he has received. However, his connection to these drug companies illustrates how doctors can be easily influenced and make suggestions that are not at the best interest of their patients or the general population.
Legal Commentary
Xarelto and Pradaxa attorneys within our firm are studying, examining and investigating current Xarelto and Pradaxa claims on behalf of people and their families who may have been injured by the drug. Some of the side effects include hemorrhaging, internal bleeding, stroke and or death. If you or a loved one has experienced any side effects while taking Xarelto or Pradaxa, contact our Xarelto and Pradaxa lawyers to discuss the facts of your potential case. We are available by phone for a free consultation at 1.866.705.7584 or by email at mn@fnlawfirm.com.